





S6 Fig. Progression-free survival (PFS) according to variant allele frequency (VAF) values. (A) Among patients with any mutations in circulating tumor DNA at baseline (baseline-ctDNA) (n=62), those with higher maximal VAF values of more than 0.059 showed significantly worse PFS (p=0.036). (B) Among patients harboring *APC* mutations (n=37), the PFS was significantly worse in those with high *APC* VAF values of more than 0.133 (p=0.019). (C) For *TP53* mutations (n=29), patients with high *TP53* VAF values of more than 0.154 tended to have shorter PFS (p=0.120). (D) For *KRAS* mutations (n=27), patients with high *KRAS* VAF values of greater than 0.081 tended to have inferior PFS (p=0.114).